Every figure on these pages traces to the 27-trial index and the statistics file — machine mirrors at trials.json and stats.json.
Provider marketing blurs drugs together; the reference layer keeps them apart. Each file states the evidence by trial name, the labeled dosing, the safety essentials, and the honest cost channels — with pipeline molecules clearly marked not purchasable.
Approved — weekly injectables
Tirzepatide
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileSemaglutide
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileZepbound (tirzepatide)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileMounjaro (tirzepatide)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileWegovy (semaglutide 2.4 mg)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileOzempic (semaglutide)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Approved — oral and older agents
Rybelsus (oral semaglutide)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileLiraglutide (Saxenda / Victoza)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Pipeline — not approved, not purchasable
Orforglipron (pipeline)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileRetatrutide (pipeline)
Evidence, dosing, safety essentials, and the 2026 cost landscape.
Reference fileCagriSema (pipeline)
Evidence, dosing, safety essentials, and the 2026 cost landscape.